Close

Elucid Bio’s vascuCAP enters IBM Imaging AI Marketplace

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Medtech Startup Raises $35M in Pulsed Field Ablation

Field Medical by Steven Mickelsen has gone on to...

Embedding Precious Metal Materials in Medical Devices

Applying radiopaque materials within the parts of medical devices...

NHS to Come Up with AI-Enabled Early Warning Systems

The National Health System – NHS has gone on...

Enhancing Robotic Surgery Precision: Millisecond Challenge

In the high-stakes world of surgical robotics, every millisecond...

Elucid Bioimaging Inc. announced that vascuCAP, Elucid Bio’s AI-enabled software for evaluating atherosclerotic plaque stability from CTA, has been added to the IBM Imaging AI Marketplace, an IBM Watson Health® solution.

The IBM Imaging AI Marketplace provides streamlined access to meaningful AI technologies designed to support leaders working in radiology and cardiology. The marketplace is designed to support healthcare providers with a solution to address the complex problem of finding, purchasing, deploying and managing innovative AI imaging applications.

“We are very excited to work with IBM Watson Health to help improve the diagnosis and treatment of cardiovascular disease by expanding access to our software,” said Blake Richards, CEO of Elucid Bio. vascuCAP is the only histologically-validated tool for objective quantitation of atherosclerotic plaque for the coronary, carotid, aorta, and femoral arteries. Interim results of the CRISP study (NCT04448353) demonstrated vascuCAP’s AI technology significantly outperformed stenosis-based guidelines in predicting risk of major adverse neurological events. The PoSTCARD (NCT04439643) trial demonstrated similar effects for predicting major adverse cardiovascular events.

“We are proud to help support meaningful advancements in the application of AI,” said Mandy Long, Vice President of Product and Strategy for IBM Watson Health Imaging & Oncology. “By partnering with Elucid and offering vascuCAP through the IBM Imaging AI Marketplace, we are demonstrating our continuous commitment to diagnostic imaging in helping clinicians gain critical clinical insights in their delivery of care.

Latest stories

Related stories

Medtech Startup Raises $35M in Pulsed Field Ablation

Field Medical by Steven Mickelsen has gone on to...

Embedding Precious Metal Materials in Medical Devices

Applying radiopaque materials within the parts of medical devices...

NHS to Come Up with AI-Enabled Early Warning Systems

The National Health System – NHS has gone on...

Enhancing Robotic Surgery Precision: Millisecond Challenge

In the high-stakes world of surgical robotics, every millisecond...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back